European Shares Mixed; Regional Inflation Data In Focus

European equities traded mixed as investors parsed regional inflation prints and geopolitics: the pan-European Stoxx 600 rose 0.2% to 602.81 after a prior 0.9% gain, while Germany's flash December CPI and HICP are awaited and French inflation eased. Notable corporate moves included Novo Nordisk jumping ~5% after launching its once-daily Wegovy pill in the U.S., TomTom up 4.1% on a renewed Uber mapping partnership, Nordex gaining 1% on new orders, Prudential announcing a $1.2bn buyback, Next raising its annual profit outlook after a 10.6% rise in full-price sales for the nine weeks to Dec. 27, 2025, and InPost surging 15% on an indicative buyout approach.

Analysis

Market structure: Novo Nordisk (NVO) is a clear winner as U.S. Wegovy launch shifts pricing power toward GLP‑1 incumbents; expect 5–15% incremental topline upside over 3–12 months versus peers while payers negotiate coverage. Parcel/logistics names face binary outcomes (buyout vs execution risk) after InPost’s approach, creating volatility spikes and dispersion in small-cap European equities. Macro prints (German flash CPI) will re‑rate cyclicals and banks within days if core inflation surprises ±0.2% m/m.

Risk assessment: Tail risks include regulatory price caps or accelerated insurer prior‑authorization for GLP‑1s (low prob, high impact) and a failed InPost deal leading to >30% drawdown in the name. Immediate (days): CPI and shop‑price data; short (weeks–months): buyback execution (Prudential PUK) and InPost special committee outcome; long (quarters): structural demand and manufacturing capacity constraints for obesity drugs. Hidden dependency: GLP‑1 upside relies on supply chain (fill/finish) and payer formulary timelines that can lag sales by 1–3 quarters.

Trade implications: Favor healthcare overweight (NVO), allocate 2–3% long via equity or call spreads (3–6 month) to capture launch momentum; size PUK long 1–2% to trade buyback arbitrage with a 10–15% target. Use STXE600 puts or futures hedges tactically if German flash CPI m/m > +0.2% or UK shop prices accelerate beyond consensus, which should widen sovereign spreads and tighten global funding.

Contrarian angles: Consensus underestimates downside from insurer restrictions—if US PBMs impose step therapy, NVO shares could correct 15–25% in 2–6 months despite launch headlines. InPost’s 15% pop likely contains deal premium; avoid chasing—prefer event‑driven long only after special committee’s non‑binding indication. Buybacks (PUK) are supportive but cap gains if capital deployment is conservative.

Key Decisions for Investors

• Establish a 2–3% long position in NVO over 3–6 months: prefer a cost‑efficient option structure (buy 6‑month 5% OTM call / sell 6‑month 20% OTM call) to capture Wegovy US launch upside; set stop‑loss at -12% and trim at +20%.
• Add a 1–2% long position in PUK (Prudential) within the next 5 trading days to play the $1.2bn buyback; target 10–15% upside over 3 months and set a hard stop at -10% if capital return details are scaled back.
• Do not initiate new long positions in InPost after the 15% gap; instead wait for special committee disclosure. If committee signals exclusivity or material bid within 30 days, consider a 1% tactical long with 20% take‑profit; otherwise short or avoid the stock.
• Hedge macro risk: buy 1–2% notional of 1–3 month STXE600 puts (or equivalent futures short) if German flash CPI m/m prints > +0.2% or UK shop price index accelerates > +0.5% m/m; this protects portfolio against a rates‑reprice and cyclicals drawdown.